Tag: Multiple Sclerosis
European Committee for Treatment and Research in Multiple Sclerosis, Sept. 18-20
FDA Approves Injectable Ocrevus Zunovo for Relapsing, Progressive MS
Phase 3 data show efficacy and safety profile similar to intravenous administration
Anti-CD20 Therapy Shows No Effect on Disability Progression in MS
Anti-CD20-treated primary progressive multiple sclerosis patients have higher risk for serious infection
Guidelines Provided for Diagnosis of Pediatric, Late-Onset Multiple Sclerosis
Unique biological features seen in children younger than 18 years, adults older than 50 years compared with typical adult-onset MS
Higher Burden of Comorbidity Linked to Worse Clinical Outcomes in MS
Presence of three or more comorbidities, two or more cardiometabolic comorbidities, one psychiatric disorder linked to evidence of disease activity
Multiple Sclerosis Linked to Lower Risk for Alzheimer Disease Pathology
Lower rate of amyloid-β plasma biomarker positivity seen in multiple sclerosis patients compared with non-MS controls
Most Patients With MS Have No Risk for Relapse After COVID-19 Vaccination
For patients with high MS activity, small increase in relapse risk seen after booster dose, especially for those not treated
Ofatumumab Effective for MS Across Racial, Ethnic Subgroups
Ofatumumab is more effective than teriflunomide for relapsing multiple sclerosis across subgroups
Parental Smoking Possibly Linked to Increased Risk for MS
In Norwegian population, associations observed between maternal smoking, maternal smoking during pregnancy and MS risk
Mesenchymal Stem Cell-Neural Progenitors Beneficial for MS
More improvement in timed 25-foot walk, six-minute walk test seen among those requiring assistance for ambulation
